p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

The HER2/c-erbB-2 gene encodes the epidermal growth factor receptorlike human homolog of the rat neu oncogene. Amplification of this gene in primary breast carcinomas has been show to correlate with poor clinical prognosis for certain cancer patients. We show here that a monoclonal antibody directed against the extracellular domain of p185HER2 specifically inhibits the growth of breast tumor-derived cell lines overexpressing the HER2/c-erbB-2 gene product and prevents HER2/c-erbB-2-transformed NIH 3T3 cells from forming colonies in soft agar. Furthermore, resistance to the cytotoxic effect of tumor necrosis factor alpha, which has been shown to be a consequence of HER2/c-erbB-2 overexpression, is significantly reduced in the presence of this antibody.

[1]  R. Snyderman,et al.  Do macrophages destroy nascent tumors? , 1979, Journal of the National Cancer Institute.

[2]  K. Semba,et al.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Povey,et al.  Identity of some human bladder cancer cell lines , 1983, Nature.

[4]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[5]  A. Elbein,et al.  Mechanism of action of tunicamycin on the UDP-GlcNAc:dolichyl-phosphate Glc-NAc-1-phosphate transferase. , 1979, Biochemistry.

[6]  J. Yokota,et al.  Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. , 1987, Cancer research.

[7]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Kraus,et al.  Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms. , 1987, The EMBO journal.

[9]  J. Mendelsohn,et al.  Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[11]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[12]  A. Ullrich,et al.  Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing , 1987, Cell.

[13]  C. Oliver,et al.  A clonal derivative of tunicamycin‐resistant Chinese hamster ovary cells with increased N‐acetylglucosamine‐phosphate transferase activity has altered asparagine‐linked glycosylation , 1987, Journal of cellular physiology.

[14]  B. Beutler,et al.  Cachectin and tumour necrosis factor as two sides of the same biological coin , 1986, Nature.

[15]  M. Greene,et al.  Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. , 1988, Oncogene.

[16]  M. Greene,et al.  Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. , 1988, Oncogene.

[17]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[18]  R. Weinberg,et al.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. , 1985, Science.

[19]  H. Shepard,et al.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Ullrich,et al.  Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. T. Lipari,et al.  Epidermal growth factor receptor tyrosine kinase phosphorylation of glucose-6-phosphate dehydrogenase in vitro. , 1987, Archives of biochemistry and biophysics.

[22]  R. Philip,et al.  Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1 , 1986, Nature.

[23]  H. Schreiber,et al.  Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity , 1983, The Journal of experimental medicine.

[24]  Robert A. Weinberg,et al.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.

[25]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[26]  B. Aggarwal,et al.  Effects of growth factors on the antiproliferative activity of tumor necrosis factors. , 1987, Cancer research.

[27]  K. Rajewsky,et al.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. , 1979, Journal of immunology.

[28]  A. Ullrich,et al.  Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.

[29]  S. Singer,et al.  Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Sato,et al.  [6] Derivation and assay of biological effects of monoclonal antibodies to epidermal growth factor receptors , 1987 .

[31]  M. Yoshida,et al.  Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line , 1986, Molecular and cellular biology.

[32]  G. Nakamura,et al.  Intracellular transport and secretion of hepatitis B surface antigen in mammalian cells , 1984, Journal of virology.

[33]  N. Nomura,et al.  Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. , 1988, Oncogene.

[34]  M. J. van de Vijver,et al.  Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene , 1987, Molecular and cellular biology.

[35]  J. Mendelsohn,et al.  Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. , 1983, Molecular biology & medicine.

[36]  B. Aggarwal,et al.  Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. , 1985, Science.

[37]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[38]  A. Ullrich,et al.  Molecular analysis of signal transduction by growth factors. , 1988, Biochemistry.

[39]  J. Vilček,et al.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[40]  E. Engleman,et al.  Production of functional human T-T hybridomas in selection medium lacking aminopterin and thymidine. , 1982, Proceedings of the National Academy of Sciences of the United States of America.